NCT06536179Recruiting
New Preclinical and Clinical Approaches to Mesothelioma
New Preclinical and Clinical Approaches to Mesothelioma, an Archetypal Inflammatory Tumor
Source: ClinicalTrials.gov · Last updated 2 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4's role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 26 Jul 2024
- Start date
- 25 Jul 2024
- Primary completion date
- 25 Jul 2025
- Lead sponsor
- Marco Emilio Bianchi
- Diseases
- Mesothelioma, Childhood cancers
- NCT number
- NCT06536179
What you commit to
- Study type: Observational
- Planned participants: 70
- From 25 Jul 2024 to the primary completion date, 25 Jul 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Lack of biopsy material.
- pregnancy.
- Unwillingness to sign the Informed Consent.
Who the study is looking for
- Patients with Mesothelioma:
- Clinical suspicion or histologically confirmed diagnosis of pleural mesothelioma.
- Candidates for surgical intervention.
- Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women.
- Capacity to comprehend the study nature and provide autonomously informed consent.
- Control Group patients:
- Absence of pleural mesothelioma but presence of other histologically confirmed diseases (neoplastic, inflammatory, or infectious).
- Candidates for surgical intervention.
- Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women.
- Ability to understand the study nature and provide autonomously informed consent.
- If the patient's diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study.
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS San Raffaele Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
| Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Coordinator of this site? Confirm its status | Naples | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.